VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Are biosimilars similar enough?

Paul Cornes, MD from the University Hospital Bristol NHS Foundation Trust, Bristol, UK takes us through the concept of batch variation in branded biologics, how it has been justified by regulators and trusted by doctors, and how the same principles and strict rules have been put in place to justify the manufacture of biosimilar drugs.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter